Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Sells $489,693.75 in Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 13,125 shares of the stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $37.31, for a total transaction of $489,693.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Jeffrey Dierks also recently made the following trade(s):

• On Monday, January 27th, Jeffrey Dierks sold 1,629 shares of Harmony Biosciences stock. The shares were sold at an average price of $38.02, for a total transaction of $61,934.58.
• On Tuesday, January 21st, Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.00, for a total value of $44,920.00.
• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The stock was sold at an average price of $37.01, for a total value of $388,864.07.

Harmony Biosciences Stock Performance

Harmony Biosciences stock opened at $38.82 on Thursday. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a twelve month low of $28.14 and a twelve month high of $41.61. The company’s 50-day moving average price is $35.20 and its 200-day moving average price is $35.22. The company has a market cap of $2.21 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. The business had revenue of $186.00 million for the quarter, compared to the consensus estimate of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.63 earnings per share. On average, equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Harmony Biosciences

Several large investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after buying an additional 436 shares during the period. Mendota Financial Group LLC boosted its stake in shares of Harmony Biosciences by 24,125.0% during the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after purchasing an additional 965 shares during the period. CWM LLC grew its holdings in Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after purchasing an additional 775 shares during the last quarter. KBC Group NV raised its position in Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after purchasing an additional 819 shares during the period. Finally, Quantbot Technologies LP bought a new stake in Harmony Biosciences in the third quarter worth about $74,000. Institutional investors own 86.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Raymond James reissued an “outperform” rating and issued a $40.00 price target on shares of Harmony Biosciences in a report on Thursday, October 10th. Needham & Company LLC restated a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a research report on Monday, January 13th. Oppenheimer reaffirmed an “outperform” rating and set a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Mizuho boosted their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, October 10th. Finally, Cantor Fitzgerald raised their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $55.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.